Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00617682 · ClinicalTrials.gov registry record · Phase 1
Maternal Immunization To Prevent Infant Otitis Media
A Phase 1 study, sponsored by National Institute on Deafness and Other Communication Disorders (NIDCD).
- Completed
- Registry status
- Phase 1
- Development phase
- 153
- Enrollment target
NCT00617682: Completed Phase 1 study, sponsored by National Institute on Deafness and Other Communication Disorders (NIDCD).
NCT00617682 is a Phase 1 study that has completed, run by National Institute on Deafness and Other Communication Disorders (NIDCD). The registered enrollment target is 153 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (155% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00617682, a Phase 1 study, has completed, sponsored by National Institute on Deafness and Other Communication Disorders (NIDCD).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 153 participants
- Enrollment target
Study Summary
The main objective of this study is to evaluate whether immunization with 9-valent pneumococcal conjugate vaccine (PNCRM9) during the third trimester of pregnancy interferes with active antibody production in offspring immunized with PNCRM7 (Prevnar) in the first six months of life.
Interventions
- BIOLOGICAL Placebo comparator
- BIOLOGICAL PNCRM9
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2000-10 |
| Est. Completion | 2004-12 |
| Phase | Phase 1 |
What the finished NCT00617682 record still lists
NCT00617682 is an interventional study that assigns participants to a tested intervention. The registered 153 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (155% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo comparator is the first listed.
NCT00617682 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00617682 about?
NCT00617682 is a clinical study titled "Maternal Immunization To Prevent Infant Otitis Media". The main objective of this study is to evaluate whether immunization with 9-valent pneumococcal conjugate vaccine (PNCRM9) during the third trimester of pregnancy interferes with active antibody production in offspring immunized with PNCRM7 (Prevnar) in the first six months of life.
What is the current status of trial NCT00617682?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 153 participants. The study started on 2000-10. Estimated completion is 2004-12.
What interventions are being tested in trial NCT00617682?
The interventions under investigation include: Placebo comparator (BIOLOGICAL), PNCRM9 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00617682?
This trial is sponsored by National Institute on Deafness and Other Communication Disorders (NIDCD), which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00617682's enrollment target sits among peer trials
153 358th of 2000 higher than 1,642 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05283265 · 153 participants · NA
Neurophysiological Mechanisms of Language Comprehension
- NCT05554393 · 153 participants · Phase 2
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- NCT05584501 · 153 participants · NA
ETE Interventions in the Dental Setting
- NCT05714839 · 153 participants · Phase 1
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia